X4 Pharmaceuticals, Inc — Director's Dealing 2021

Mar 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: X4 Pharmaceuticals, Inc (XFOR)
CIK: 0001501697
Period of Report: 2021-03-24

Reporting Person: Cadavid Diego (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-24	Common Stock	A	8035	—	Acquired	8035	Direct

Footnotes

F1: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 11, 2022, February 11, 2023 and February 11, 2024 subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.

F2: Represents unvested restricted stock units.